[2026] Pass SCDM CCDM Exam Updated 152 Questions
Get 2026 Updated Free SCDM CCDM Exam Questions and Answer
SCDM CCDM Exam Syllabus Topics:
| Topic | Details |
|---|---|
| Topic 1 |
|
| Topic 2 |
|
| Topic 3 |
|
| Topic 4 |
|
| Topic 5 |
|
NEW QUESTION # 68
In development of CRF Completion Guidelines (CCGs), which is a minimum requirement?
- A. CCGs must include a version control on the updated document
- B. CCGs are designed from the perspective of the Study Biostatistician to ensure that the data collected can be analyzed
- C. CCGs are developed with representatives of Data Management, Biostatistics, and Marketing departments
- D. CCGs must be signed before database closure to include all possible protocol changes affecting CRF completion
Answer: A
Explanation:
Case Report Form Completion Guidelines (CCGs) are essential study documents that instruct site staff on how to complete each field of the CRF correctly. A minimum requirement for CCGs, according to Good Clinical Data Management Practices (GCDMP, Chapter: CRF Design and Data Collection), is that they must include version control.
Option A describes an important design consideration but not a minimum compliance requirement. Option B is inaccurate, as CCGs must be approved and implemented before data collection begins, not after. Option D includes an irrelevant stakeholder (Marketing).
Therefore, option C-"CCGs must include a version control on the updated document"-is correct and compliant with CCDM and GCP standards.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: CRF Design and Data Collection, Section 4.3 - Development and Maintenance of CRF Completion Guidelines ICH E6(R2) GCP, Section 8.2.1 - Essential Documents and Version Control Requirements
NEW QUESTION # 69
Which of the following factors can be tested through a second test transfer?
- A. Transfer method
- B. Transfer frequency
- C. Change management
- D. File format
Answer: D
Explanation:
In the context of database design and external data management, a test data transfer (or trial data load) is performed to ensure the proper configuration, structure, and integrity of data imported from an external vendor or system. The second test transfer is specifically useful to confirm that data structures and formats are consistently aligned between the sending and receiving systems after initial adjustments have been made from the first test.
According to the Good Clinical Data Management Practices (GCDMP), the file format - including variables, data types, field lengths, delimiters, and encoding - must be validated during test transfers to confirm compatibility and ensure accurate loading into the target database. Once the initial test identifies and corrects errors (e.g., mismatched variable names or data types), the second transfer verifies that the corrections have been implemented correctly and that the file structure functions as intended.
Testing change management (A) involves procedural controls, not data transfers. The transfer method (C) and transfer frequency (D) are validated during initial process setup, not during subsequent test transfers.
Therefore, option B (File format) is correct, as the second test transfer verifies the technical integrity of the file structure before live production transfers begin.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: External Data Transfers and Data Integration, Section 5.2 - Test Transfers and File Validation FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.3 - Data Import and Validation Controls
NEW QUESTION # 70
A study collects blood pressure. Which is the best way to collect the data?
- A. High/Low radio button
- B. Two continuous variables
- C. Coding a verbatim field with a MedDRA diagnosis
- D. Check boxes for twenty-point increments
Answer: B
Explanation:
Blood pressure is a quantitative physiological measurement, typically consisting of two continuous numeric values: systolic and diastolic pressure. Therefore, the most appropriate and scientifically valid method of data collection is to use two continuous variables (e.g., systolic = 120 mmHg, diastolic = 80 mmHg).
According to the GCDMP (Chapter: CRF Design and Data Collection), data fields must be designed to capture the most precise, accurate, and analyzable form of clinical data. Numeric data should be collected using numeric data types to allow for range checks, calculations (e.g., mean arterial pressure), and statistical analysis.
Options such as categorical representations (radio buttons or check boxes) introduce rounding, data loss, and analytic limitations. Coding a verbatim diagnosis (option A) is inappropriate for numeric vital sign data and violates the principle of capturing data at the most granular level.
Thus, the correct and validated method per CCDM standards is two continuous variables, ensuring accuracy, traceability, and analytical flexibility.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: CRF Design and Data Collection, Section 4.2 - Best Practices for Quantitative Data Capture ICH E6 (R2) Good Clinical Practice, Section 5.5.3 - Data Accuracy and Collection Standards FDA Guidance for Industry: Electronic Source Data in Clinical Investigations, Section 4.3 - Data Format and Structure Requirements
NEW QUESTION # 71
Who has primary responsibility for ensuring accurate completion of the CRF?
- A. Clinical Data Manager
- B. Investigator
- C. Site Coordinator
- D. Clinical Research Associate
Answer: B
Explanation:
The Investigator holds the primary responsibility for ensuring the accuracy, completeness, and timeliness of Case Report Form (CRF) entries. This responsibility is mandated by regulatory requirements under ICH E6(R2) Good Clinical Practice (GCP).
The investigator may delegate CRF completion to a qualified designee (e.g., site coordinator), but the ultimate accountability remains with the investigator. The investigator's signature (electronic or manual) on the CRF serves as certification that the data accurately reflect the source documents and the patient's participation.
The GCDMP (Chapter: CRF Design and Data Collection) reinforces this by stating that while data managers ensure design quality and CRAs verify consistency with source data, the investigator is legally responsible for CRF accuracy.
Thus, option D (Investigator) is correct, as it aligns with both GCP and CCDM standards.
Reference (CCDM-Verified Sources):
ICH E6(R2) GCP, Section 4.9 - Records and Reports (Investigator Responsibilities) SCDM GCDMP, Chapter: CRF Design and Data Collection, Section 5.1 - Investigator's Role in Data Accuracy FDA 21 CFR Part 312.62 - Investigator Recordkeeping and Record Retention
NEW QUESTION # 72
Which is the best reason why front-end checks are usually kept minimal, when compared to back-end checks, in a paper-based clinical study?
- A. Data entry staff should be able to enter a value into the database just as it appears in the paper CRF
- B. There are approvals required to raise a Data Clarification Form which could take time
- C. Data review can be performed at a later time due to the paper-based studies being smaller in size
- D. There is no need to alert the site personnel immediately about a data issue, as the study has happened already
Answer: A
Explanation:
In paper-based clinical studies, front-end data checks (those performed during data entry) are intentionally kept minimal to ensure that data are entered exactly as recorded on the paper CRF. This principle ensures data integrity by maintaining fidelity between source and electronic records before any cleaning or edit validation occurs.
The GCDMP (Chapter: Data Validation and Cleaning) explains that data entry operators should input values as written, even if they appear incorrect or inconsistent, because the purpose of front-end checks is not to interpret but to capture data faithfully. The back-end edit checks-performed later by data managers-are designed to identify inconsistencies, out-of-range values, or logical errors that require clarification through queries.
This approach separates data capture from data cleaning, minimizing bias and preserving original investigator input. Hence, option A accurately states the rationale for keeping front-end checks minimal in paper-based studies.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Data Validation and Cleaning, Section 4.2 - Data Entry, Edit Checks, and Query Process ICH E6(R2) GCP, Section 5.5.3 - Data Handling and System Controls FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.1 - Data Entry and Verification Processes
NEW QUESTION # 73
Which metric reveals the timeliness of the site-work dimension of site performance?
- A. Time from site contract execution to first patient enrolled
- B. Time from final protocol to first patient enrolled
- C. Time from Last Patient Last Visit to database lock
- D. Median and range of time from query generation to resolution
Answer: D
Explanation:
The site-work dimension of site performance evaluates how efficiently sites manage and resolve data-related tasks - particularly query resolution, data entry, and correction timelines. Among the given metrics, the median and range of time from query generation to resolution (D) directly measures the site's responsiveness and data management efficiency.
According to the GCDMP (Chapter on Metrics and Performance Measurement), this indicator helps identify sites that delay query resolution, which can impact overall study timelines and data quality. Tracking this metric allows the data management team to proactively provide additional training or communication to underperforming sites.
Other options measure different aspects of project progress:
A reflects overall database closure speed.
B and C relate to study startup and enrollment readiness, not ongoing data work.
Thus, option D accurately represents a site performance timeliness metric, aligning with CCDM principles for operational performance measurement.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Metrics and Performance Management, Section 5.4 - Site Query Resolution Metrics ICH E6(R2) Good Clinical Practice, Section 5.18 - Monitoring and Site Performance Oversight
NEW QUESTION # 74
A study team member wants to let sites enroll patients before the system is ready. Which are important considerations?
- A. Starting the study prior to the EDC system being ready will delay processing of milestone-based site payments
- B. There is no way to identify, report and track adverse events and serious adverse events without the EDC system in place
- C. If the study were audited, enrolling subjects prior to having the EDC system ready would become an audit finding
- D. Without the ability to capture the data electronically, the data cannot be checked or used to monitor and manage the study
Answer: D
Explanation:
Enrolling subjects before the Electronic Data Capture (EDC) system is ready poses major data integrity and compliance risks. The primary issue is that data cannot be accurately captured, validated, or monitored without the system in place.
Per the GCDMP (Chapter: Data Management Planning and Study Start-up), data collection systems must be fully validated, tested, and released before enrollment begins to ensure:
Real-time data entry and quality control
Proper tracking of adverse events (AEs/SAEs)
Audit trails and traceability for regulatory compliance
Option A highlights the most critical consequence - without an operational EDC, data collection and verification processes cannot occur, compromising data quality and study oversight.
While options B, C, and D may be partially true, they are secondary effects. The fundamental consideration is data capture capability and monitoring control, making option A correct.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Data Management Planning and Study Start-up, Section 4.2 - EDC Readiness and System Validation ICH E6(R2) GCP, Section 5.5.3 - Computerized Systems Validation Before Use FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.1 - System Qualification Prior to Data Entry
NEW QUESTION # 75
In an EDC study, an example of an edit check that would be inefficient to run at data entry is a check:
- A. Against a valid numeric range.
- B. Across visits for consistency.
- C. On the format of a date.
- D. Against a valid list of values.
Answer: B
Explanation:
In Electronic Data Capture (EDC) systems, edit checks are categorized based on when and how they are executed - typically immediate (at data entry) or batch (post-entry). Checks that require data from multiple visits or forms are generally inefficient to run at data entry because they depend on information that may not yet exist in the system.
According to the Good Clinical Data Management Practices (GCDMP, Chapter: Data Validation and Cleaning), cross-visit consistency checks - such as comparing baseline and follow-up blood pressure or verifying date order between screening and dosing - should be executed as batch or scheduled validations, not at the point of data entry. Running these complex checks in real time can slow system performance, increase query load unnecessarily, and confuse site users if related data are not yet entered.
Conversely, edit checks against valid ranges, formats, or predefined value lists (options A, C, and D) are simple, local validations ideally performed immediately at data entry to prevent basic errors.
Therefore, cross-visit consistency checks (Option B) are best executed later, making them inefficient for real-time data entry validation.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Validation and Cleaning, Section 6.4 - Real-Time vs. Batch Edit Checks FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations - Section on Edit Checks and Data Validation Logic CDISC SDTM Implementation Guide - Section on Temporal Data Consistency Validation
NEW QUESTION # 76
Which of the following data verification checks would most likely be included in a manual or visual data review step?
- A. Checking adverse event treatments against concomitant medications
- B. Checking an entered value against a valid list of values
- C. Checking mandatory fields for missing values
- D. Checking a value against a reference range
Answer: A
Explanation:
Manual or visual data review is used to identify complex clinical relationships and contextual inconsistencies that cannot be detected by automated edit checks.
According to the GCDMP (Chapter: Data Validation and Cleaning), automated edit checks are ideal for structured validations, such as missing fields (option C), reference ranges (option D), or predefined value lists (option A). However, certain clinical cross-checks-such as verifying adverse event treatments against concomitant medication records-require clinical judgment and contextual understanding.
For example, if an adverse event of "severe headache" was reported but no analgesic appears in the concomitant medication log, the data may warrant manual review and query generation. These context-based checks are best performed by trained data reviewers or medical data managers during manual data review cycles.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Validation and Cleaning, Section 6.3 - Manual Review and Clinical Data Consistency Checks ICH E6 (R2) Good Clinical Practice, Section 5.18.4 - Clinical Data Review Responsibilities FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations - Data Verification Principles
NEW QUESTION # 77
Which is the best way to see site variability in eligibility screening?
- A. List eligibility waivers by site
- B. Graph enrollment by site
- C. Plot eligibility rate by site
- D. Summarize screening rate by site
Answer: C
Explanation:
To identify site variability in eligibility screening, the most effective approach is to plot eligibility rate by site. This allows visual detection of differences in how well each site screens subjects according to protocol-defined inclusion and exclusion criteria.
The GCDMP (Chapter: Data Quality Assurance and Metrics) emphasizes the importance of graphical analysis for identifying anomalies and site-level performance variability. By plotting the eligibility rate by site, data managers and clinical operations teams can quickly identify outliers-sites that screen too many or too few eligible subjects-indicating potential training issues, misunderstanding of inclusion/exclusion criteria, or even possible protocol deviations.
While summarizing screening rate (B) provides useful numeric data, it lacks visual comparability. Listing waivers (A) or enrollment counts (C) provide limited insights into eligibility consistency.
Therefore, option D-Plot eligibility rate by site-is the best analytic and visualization practice to assess site variability in screening outcomes.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Data Quality Assurance and Control, Section 6.1 - Use of Metrics and Graphical Review for Site Performance ICH E6(R2) GCP, Section 5.18.4 - Identification of Systematic or Site-Specific Issues
NEW QUESTION # 78
The Scope of Work would answer which of the following information needs?
- A. To look up the date of the next clinical monitoring visit for a specific site
- B. To determine the number of data transfers budgeted for a project
- C. To look up which visit PK samples are taken
- D. To find the name and contact information of a specific clinical data associate
Answer: B
Explanation:
The Scope of Work (SOW) is a project management document that defines what services are included in the work agreement between the sponsor and the CRO or vendor. It outlines deliverables, responsibilities, timelines, and budget allocations.
According to the GCDMP (Chapter: Project Management in Data Management), the SOW includes specifications such as:
The number and frequency of data transfers,
Database build and lock milestones,
Quality control deliverables, and
Resource allocation for data management tasks.
The SOW does not cover operational site-level details such as monitoring schedules (B), protocol sampling details (C), or personnel contact lists (D).
Therefore, option A (number of data transfers budgeted for a project) correctly identifies a use case directly addressed in the SOW.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: Project Management, Section 4.1 - Scope of Work and Resource Planning ICH E6(R2) GCP, Section 5.5 - Sponsor Oversight and Data Management Responsibilities PMI Project Management Framework - Scope Definition and Deliverable Specifications
NEW QUESTION # 79
A study uses commercially available activity monitors and collects data for each patient weekly by selecting and downloading the data from the manufacturer's website. There are 100 patients in the study and it takes the Data Manager 20 minutes per file to download, import, and process the dat a. Assuming that the distribution of work is uniform over the six-month trial, how many Data Managers are needed for the activity data alone?
- A. Two Data Managers per month
- B. Ten percent of a Data Manager per month
- C. Fifty percent of a Data Manager per month
- D. One Data Manager per month
Answer: D
Explanation:
This question tests workload estimation and resource planning, which are fundamental competencies outlined in the Good Clinical Data Management Practices (GCDMP, Chapter on Project Management in Data Management). The task is to determine the Data Manager effort required based on the frequency and duration of data collection and processing activities.
Let's calculate step by step:
Number of patients: 100
Frequency: Weekly (once per week)
Duration: 6 months ≈ 26 weeks
Time per file: 20 minutes
Total time per week:
100 patients × 20 minutes = 2,000 minutes per week
= 2,000 ÷ 60 = 33.3 hours per week
Total hours over 6 months:
33.3 hours/week × 26 weeks = 866 hours total
A full-time Data Manager typically works ~160 hours per month, so over six months:
160 × 6 = 960 hours total full-time capacity.
Therefore, the workload of 866 hours is approximately equivalent to one full-time Data Manager working across the six-month period:
866 ÷ 960 ≈ 0.9 FTE (Full-Time Equivalent).
This aligns most closely with Option D: One Data Manager per month (i.e., a full-time resource is required throughout the duration of the trial).
According to the GCDMP Project Management chapter, accurate resource estimation is critical in ensuring data management timelines are met without overloading staff or compromising data quality. The estimation process must consider not just the raw data download time but also associated data processing, verification, and upload into the clinical database.
Other options underestimate the effort significantly:
A (10%) and B (50%) do not account for cumulative weekly workload across multiple patients.
C (Two Data Managers) overestimates, as one Data Manager working full-time can manage the load efficiently.
Therefore, Option D is correct - approximately one full-time Data Manager (1.0 FTE) is required for the activity data alone during the six-month trial.
Reference (CCDM-Verified Sources):
Society for Clinical Data Management (SCDM), Good Clinical Data Management Practices (GCDMP), Chapter: Project Management in Data Management, Section 5.3 - Workload Estimation and Resource Allocation SCDM GCDMP, Chapter: Data Handling and Processing - Effort Estimation for Repetitive Data Tasks ICH E6 (R2) Good Clinical Practice, Section 5.1 - Quality Management and Resource Planning FDA Guidance for Industry: Electronic Source Data in Clinical Investigations, Section 4.3 - Operational Considerations for Data Management Activities
NEW QUESTION # 80
In a physical therapy study, range of motion is assessed by a physical therapist at each site using a study-provided goniometer. Which is the most appropriate quality control method for the range of motion measurement?
- A. Reviewing data listings for illogical changes in range of motion between visits
- B. Independent assessment by a second physical therapist during the visit
- C. Comparison to the measurement from the previous visit
- D. Programmed edit checks to detect out-of-range values upon data entry
Answer: B
Explanation:
In this scenario, the variable of interest-range of motion (ROM)-is a clinically measured, observer-dependent variable. The accuracy and reliability of such data depend primarily on the precision and consistency of the measurement technique, not merely on data entry validation. Therefore, the most appropriate quality control (QC) method is independent verification of the measurement by a second qualified assessor during the visit (Option D).
According to the Good Clinical Data Management Practices (GCDMP, Chapter on Data Quality Assurance and Control), quality control procedures must be tailored to the nature of the data. For clinically assessed variables, especially those involving human judgment (e.g., physical measurements, imaging assessments, or subjective scoring), real-time verification by an independent qualified assessor ensures that data are valid and reproducible at the point of collection. This approach directly addresses measurement bias, observer variability, and instrument misuse, which are primary sources of data error in clinical outcome assessments.
Other options, while valuable, address only data consistency or plausibility after collection:
Option A (comparison to previous visit) and Option C (reviewing data listings) are retrospective data reviews, suitable for identifying trends but not preventing measurement error.
Option B (programmed edit checks) detects only extreme or impossible values, not measurement inaccuracies due to technique or observer inconsistency.
The GCDMP and ICH E6 (R2) Good Clinical Practice guidelines emphasize that data quality assurance should begin at the source, through standardized procedures, instrument calibration, and dual assessments for observer-dependent measures. Having an independent second assessor ensures inter-rater reliability and provides direct confirmation that the recorded value reflects an accurate and valid measurement.
Reference (CCDM-Verified Sources):
Society for Clinical Data Management (SCDM), Good Clinical Data Management Practices (GCDMP), Chapter: Data Quality Assurance and Control, Section 7.4 - Measurement Quality and Verification ICH E6 (R2) Good Clinical Practice, Section 2.13 - Quality Systems and Data Integrity FDA Guidance for Industry: Patient-Reported Outcome Measures and Clinical Outcome Assessment Data, Section 5.3 - Quality Control of Clinician-Assessed Data SCDM GCDMP Chapter: Source Data Verification and Quality Oversight Procedures
NEW QUESTION # 81
During testing of an ePRO system, a test fails. Which information should be found in the validation documentation?
- A. Training requirements
- B. Reconciliation datapoints
- C. Root cause analysis of the system errors
- D. Expected and actual results
Answer: D
Explanation:
When a system validation test fails during Electronic Patient-Reported Outcome (ePRO) system testing, the validation documentation must record the expected results (what should have occurred) and the actual results (what occurred).
According to the GCDMP (Chapter: Database Validation and Testing), proper system validation documentation ensures traceability, reproducibility, and compliance with FDA 21 CFR Part 11 and ICH E6 (R2). Each test case must include:
Test objective,
Preconditions,
Test steps,
Expected results,
Actual results, and
Pass/fail status.
If a test fails, this documentation provides the objective evidence necessary for deviation handling, issue resolution, and re-testing. While a separate root cause analysis may be performed later (option D), the validation record itself must focus on verifying outcomes against predefined expectations.
Therefore, the correct answer is B - Expected and actual results.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Database Validation and Testing, Section 4.4 - Documentation of Test Results FDA 21 CFR Part 11 - Validation Requirements (Section 11.10(a)) ICH E6 (R2) GCP, Section 5.5.3 - Computer System Validation and Documentation
NEW QUESTION # 82
There is a modification to the CRF and a sudden increase in the number of queries generated in the EDC system. Which action is most likely to reduce the number of queries?
- A. Review the edit checks for correctness
- B. Make some of the existing edit checks manually
- C. Have the monitor close the queries
- D. Introduce a source data verification process
Answer: A
Explanation:
When a CRF modification leads to a sudden increase in EDC queries, the most likely cause is an error or misconfiguration in the edit checks introduced during or after the change. Therefore, the first step should be to review the edit checks for correctness.
The GCDMP (Chapter: Database Design and Validation) emphasizes that any database or CRF modification should trigger retesting of affected validation rules. Incorrect logic, thresholds, or missing conditional statements in automated edit checks can cause false or redundant queries, leading to unnecessary data management burden and site frustration.
Manually handling edit checks (option A) or adding SDV (option B) does not address the root cause. Having monitors close queries (option D) would mask the problem rather than resolve it.
Thus, the correct corrective measure is Option C - review and validate the edit checks to ensure proper functionality.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Database Design and Validation, Section 5.5 - Edit Check Testing and Review ICH E6 (R2) GCP, Section 5.5.3 - Validation and Change Control for Electronic Systems FDA 21 CFR Part 11 - System Validation and Change Documentation
NEW QUESTION # 83
......
Verified CCDM exam dumps Q&As with Correct 152 Questions and Answers: https://www.testinsides.top/CCDM-dumps-review.html
CCDM Dumps PDF and Test Engine Exam Questions: https://drive.google.com/open?id=1UDAbQrZ-yiSRcQSsVQGtxgZDAJEgVpS9